Multiple sclerosis
By recognising the signs of PTSD with an MS diagnosis and delivering the appropriate support, patients are empowered to focus on improving their quality of life, says Dr Roy Aloni, head of Psychological Unit, Multiple Sclerosis Center, Sheba Medical Center, and BelongMs expert
Multiple sclerosis (MS) is an autoimmune disease of the central nervous system that affects both the brain and the spinal cord. With MS, the immune system attacks myelin—a protective layer that covers the nerve fibres— allowing the degeneration of groups of neurons, which affects a variety of functions. Multiple sclerosis (MS) is an autoimmune disease of the central nervous system that affects both the brain and the spinal cord. With MS, the immune system attacks myelin—a protective layer that covers the nerve fibres— allowing the degeneration of groups of neurons, which affects a variety of functions.
MS-Related Stress In most cases, MS is diagnosed at a young age, which can be a significant emotional burden with extensive psycho-social consequences that affect the patient’s quality of life. 
Tiny 3D models that mimic vital aspects of the human nervous system have been developed in a step that could accelerate drug research for neurological conditions such as multiple sclerosis (MS). The millimetre-wide models - created using stem cells from human skin samples - will be used to study myelin, an insulating substance that helps nerve cells communicate with each other. Researchers say the models are the most natural representation of human myelination developed in a lab and are a promising platform for studying neurological diseases and for testing drugs for conditions linked to myelin loss, including MS. Nerve cells are found in the brain and the spinal cord and connect to each other with branch-like links called axons, which have an insulating coat similar to electric cabling. This insulating coat is called myelin, and it aids the electrical and chemical information flow between cells.
When Jessie Ace woke on her last day of university, unable to feel the whole left hand side of her body, her dreams of becoming an illustrator lay in tatters.
Having already clinched a book deal, which had been her ambition since childhood, Jessie’s future career plans had seemed to be in the ascendancy. But from that moment, and with her subsequent diagnosis of Multiple Sclerosis (MS) at the age of only 22, Jessie was forced to delay her ambitions - but was adamant she would never give up. And now, eight years on, the determination and positivity which characterise Jessie’s everyday life have resulted in her publishing her first illustrated colouring book for children.
New MRI techniques to show what is happening in the brains of people with multiple sclerosis (MS) could have the potential to predict disability from the early stages of their condition, new research has revealed.
Through assessing microscopic changes in the brain at the earliest opportunity using MRI, scientists now believe this has the potential to indicate the level of disability the person may face in the future. The study by University College London (UCL), funded by the MS Society and Rosetrees Trust, combined advanced MRI techniques to show the smallest of changes happening in the MS brain.
More than a third of people who have Multiple Sclerosis (MS) keep their condition secret, it has been revealed.
In a survey of over 800 people living with MS, 35 per cent said they have kept their diagnosis private.
Three new subtypes of multiple sclerosis (MS) have been identified by using artificial intelligence (AI).
The new MS subtypes were defined as 'cortex-led', 'normal-appearing white matter-led', and ‘lesion-led.' The study, by scientists at UCL, has been hailed as potentially being key in identifying those people more likely to have disease progression and help target treatments more effectively.
A world-first trial is being launched in the UK into whether drugs already on the market can prevent multiple sclerosis (MS) from worsening and even reverse the disabilities it causes.
The Octopus trial will investigate the potential benefits of using a number of different medications at once, in the hope of finding effective new treatments up to three times faster than if the medicines were trialled separately.
Approval has been given for use of a multiple sclerosis (MS) medication in Scotland, with a final decision on its introduction in England and Wales expected later this year.
The medication ozanimod, or Zeposia, has been given approval by the Scottish Medicines Consortium (SMC) for people with active relapsing remitting MS. Ozanimod is a disease modifying therapy which is taken as a tablet and traps immune T-cells in the body’s lymph nodes.
Vision in patients with multiple sclerosis (MS) could be improved through the use of medication, a new study has found.
A mice study investigated the effect of indazole chloride (IndCl) on the pathology and function of the afferent visual pathway for the first time, which includes the eyes, optic nerve, and all brain structures responsible for receiving, transmitting, and processing visual information. "IndCl has been previously shown in mice to reduce motor disability, increase myelination, and neuroprotection in the spinal cord and corpus callosum," says Seema Tiwari-Woodruff, a professor of biomedical sciences at the UC Riverside School of Medicine and the study's lead author.
The effect of medication Tysabri on cognitive fatigue in people with multiple sclerosis (MS) is to be analysed in a new research study.
The study will look at how the medication, also known as natalizumab, impacts cognitive fatigue in individuals with relapsing and remitting MS. Most people living with MS report symptoms of cognitive fatigue, which can adversely affect their ability to perform activities in their everyday lives. Statistics show that over 40 per cent consider such fatigue their most troubling symptom.
